Trials / Active Not Recruiting
Active Not RecruitingNCT05519865
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
A Randomized, Double-blind, Controlled, Multi-center Phase II Clinical Trial of Tucidinostat Combined With Tislelizumab as First-line Treatment for PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Chipscreen Biosciences, Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blind, Controlled, Multi-center Phase 2 Clinical study to Investigate the Efficacy and Safety of Tucidinostat (Chidamide) Combined with Tislelizumab as First-line Treatment for PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tucidinostat | 30mg orally BIW |
| DRUG | Tislelizumab | 200 mg intravenously (IV) Q3W |
Timeline
- Start date
- 2022-10-26
- Primary completion
- 2024-10-01
- Completion
- 2024-10-01
- First posted
- 2022-08-29
- Last updated
- 2024-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05519865. Inclusion in this directory is not an endorsement.